​

Orchestra BioMed Ownership | Who Owns Orchestra BioMed?

OverviewRevenueFinancialsChart

Orchestra BioMed Ownership Summary

Orchestra BioMed is owned by 51.03% institutional investors, 21.82% insiders, and 27.15% retail investors.

OBIO Ownership Benchmark

TypeName% Inst% Insiders% Retail
StockOrchestra BioMed51.03%21.82%27.15%
SectorHealthcare Stocks 57.39%9.93%32.68%
IndustryBiotech Stocks 68.48%9.65%21.87%

Institutional Ownership Trends

DateHoldingsChange %SharesChange %OwnershipChange %Increased PositionChange %Decreased PositionChange %
Dec 31, 20245210.64%19,199,4870.91%512.00%3425.93%7-22.22%
Sep 30, 2024472.17%19,025,94933.83%503.21%27-10.00%928.57%
Jun 30, 2024469.52%14,216,9936.62%392.86%3076.47%7-58.82%
Mar 31, 2024427.69%13,334,7300.49%372.34%17-15.00%17142.86%
Dec 31, 202339-7.14%13,269,9801.35%392.89%20-52.38%7-

Recent Insider Transactions

DateNameRoleActivityValue
Dec 23, 2024Hochman David P See RemarksBuy$18.64K
Dec 19, 2024Taylor Andrew Lawrence Chief Financial OfficerBuy$4.83K
Dec 18, 2024Hochman David P See RemarksBuy$24.55K
Sep 25, 2024Hochman David P See RemarksBuy$9.48K
Sep 25, 2024Hochman David P See RemarksBuy$9.46K

Insider Transactions Trends

DateBuySell
2025 Q1--
2024 Q43-
2024 Q368
2024 Q24-
2024 Q1--

OBIO Ownership FAQ

Who Owns Orchestra BioMed?

Orchestra BioMed shareholders are primarily institutional investors at 51.03%, followed by 21.82% insiders and 27.15% retail investors. The average institutional ownership in Orchestra BioMed's industry, Biotech Stocks , is 68.48%, which Orchestra BioMed falls below.

Does Blackrock own Orchestra BioMed?

BlackRock is not among the top 10 institutional shareholders of Orchestra BioMed.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

  • Customize your own personal stocks lists, views and charts

  • Choose from hundreds of fields, up to 15 years of history

  • Conduct deep comparison analysis

  • Discover trending investment themes

  • Find your next best investment

  • Research stocks using tools